Publication:
Cell-main spectra profile screening technique in simulation of circulating tumour cells using maldi-tof mass spectrometry

dc.contributor.authorWararat Chiangjongen_US
dc.contributor.authorSebastian Chakrit Bhakdien_US
dc.contributor.authorNoppawan Woramongkolchaien_US
dc.contributor.authorThitinee Vanichapolen_US
dc.contributor.authorNutkridta Pongsakulen_US
dc.contributor.authorSuradej Hongengen_US
dc.contributor.authorSomchai Chutipongtanateen_US
dc.contributor.otherChulalongkorn Universityen_US
dc.contributor.otherFaculty of Medicine Ramathibodi Hospital, Mahidol Universityen_US
dc.contributor.otherMahidol Universityen_US
dc.contributor.otherX-ZELL Biotech Pte Ltd.en_US
dc.date.accessioned2022-08-04T08:07:06Z
dc.date.available2022-08-04T08:07:06Z
dc.date.issued2021-08-01en_US
dc.description.abstractCirculating atypical cells (CAC) are released from a primary tumour site into peripheral blood and are indicators of cancer metastasis. CAC occur at very low frequency in circulating blood, and their detection remains challenging. Moreover, white blood cells (WBC) are the major contami-nant in enriched CAC samples. Here, we developed matrix-assisted laser desorption ionization–time of flight mass spectrometry (MALDI-TOF MS) as a novel CAC characterization platform. Main spectra profiles (MSP) of normal and cancer cells were generated by MALDI-TOF MS, and a cell-main spectra database was then compiled and analysed using the MALDI Biotyper software. Logarithmic scores accurately predicted distinct cell types. The feasibility of this workflow was then validated using simulated samples, which were prepared by 5000 WBC of three healthy individuals spiked with varying numbers (3, 6, 12, 25, 50, and 100) of lung, colon, or prostate cancer cells. MALDI-TOF MS was able to detect cancer cells down to six cells over the background noise of 5000 WBC with significantly higher predictive scores as compared to WBC alone. Further development of cell-MSP database to cover all cancer types sourced from cell lines and patient tumours may enable the use of MALDI-TOF MS as a cancer-screening platform in clinical settings in the future.en_US
dc.identifier.citationCancers. Vol.13, No.15 (2021)en_US
dc.identifier.doi10.3390/cancers13153775en_US
dc.identifier.issn20726694en_US
dc.identifier.other2-s2.0-85111113624en_US
dc.identifier.urihttps://repository.li.mahidol.ac.th/handle/123456789/76091
dc.rightsMahidol Universityen_US
dc.rights.holderSCOPUSen_US
dc.source.urihttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85111113624&origin=inwarden_US
dc.subjectBiochemistry, Genetics and Molecular Biologyen_US
dc.subjectMedicineen_US
dc.titleCell-main spectra profile screening technique in simulation of circulating tumour cells using maldi-tof mass spectrometryen_US
dc.typeArticleen_US
dspace.entity.typePublication
mu.datasource.scopushttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85111113624&origin=inwarden_US

Files

Collections